All Resources

Patented Medicine Prices Review Board (PMPRB) • December 05, 2022

The Suspension and Reformulation of the PMPRB Guidelines is Urgently Required: IMC Response to PMPRB 2022 Guidelines Proposals

Learn more | View

Private Drug Coverage • November 25, 2022

Cost Drivers: Analysis of Private Drug Plans in Canada 2022

Learn more | View

Access to Medicine • November 17, 2022

Innovative Agreements Framework

Learn more | View

Patented Medicine Prices Review Board (PMPRB) • November 09, 2022

Letter to The Honourable Jean-Yves Duclos, P.C., M.P.

Learn more | View

Patented Medicine Prices Review Board (PMPRB) • November 09, 2022

Letter to The Hon. Chrystia Freeland, P.C., M.P.

Learn more | View

Patented Medicine Prices Review Board (PMPRB) • November 09, 2022

Letter to The Honourable Mary Ng, P.C., M.P.

Learn more | View

Patented Medicine Prices Review Board (PMPRB) • November 09, 2022

Ministerial PMPRB Guideline Letter to The Hon. François-Philippe Champagne, P.C., M.P.

Learn more | View

Economic Impact • October 07, 2022

Pre-Budget Consultations in Advance of the 2023 Budget

Learn more | View

Access to Medicine • July 06, 2022

Developing a Pan-Canadian Genomics Strategy: Innovative Medicines Canada Response

Learn more | View

Access to Medicine • February 05, 2022

Bluesky Project

Reimagining Canada’s Approval and Reimbursement System for Innovative Medicines February 2022…

Learn more | View

Ethics • January 01, 2022

2022 Code of Ethical Practices

Learn more | View

Drugs for Rare Diseases (DRD) • September 15, 2021

Addendum to IMC Submission on Drugs for Rare Diseases

Innovative Medicines Canada provides Health Canada with additional input regarding IMC’s March 2021 consultation submission on drugs for rare diseases….

Learn more | View